Automation is the trend.
It is learned that the Siidi diagnostics , which focuses on accurate tumor diagnosis, recently completed its 280 million yuan financing for the diagnostic business sector. This round of financing was led by China Resources Pharmaceutical Industry Investment Fund, jointly led by Luxin Venture Capital and Shandong Transportation Industry Development Fund, Shanghai Zhangjiang Technology Venture Capital Co., Ltd., Xinzhongli, Guangzhou Qudao Assets , Guangzhou Guofa Venture Capital and other funds jointly participate in the investment, Ekai Capital serves as the exclusive financial consultant . Among them, Luxin Venture Capital, Xinzhongli, and Guangzhou Qudao Assets are additional investments as old shareholders. This is also the first round of independent financing after the company split its diagnostic company for the first time.
It is reported that the financing will be mainly used for product research and development, including the subsequent pipeline development of its ANDiS closed automated NGS platform, the development of an exosome platform-based tumor early diagnosis product pipeline, and the third-party detection service product pipeline. Expansion.
Sididi diagnosis was originally Sididi Precision Medicine ( Reported in detail ), the precise diagnostics business segment, which mainly focuses on accurate tumor diagnosis; the other segment is the drug development business, which has now been split Completed the construction of a red-chip architecture for Scitec Pharmaceuticals, focusing on the development of oncology drugs. They were separated from Scitec in 2018. It is reported that Dr. Gong Zhaolong, the former CEO of Credidi Precision Medicine, will continue to serve as the chairman and CEO of Credidi Pharmaceutical; in addition, the company’s first US $ 40 million financing has been put in place after the split, and the first NDA is planned to be submitted in 2020.
According to Dr. Xiong Lei, the founder and chairman and CEO of Credidiom Diagnostics, It is mainly based on the rapid development of the business and the need to focus on different capital markets: On the one hand, the diagnostic business and the drug development business have different rhythms, and the demand for capital has changed greatly. The separation is more conducive to the former and is lighter. Quantitative development; on the other hand, the company plans to list the two major business segments in different capital markets in the future.
With regard to Didi diagnosis, it currently has third-party medical testing services and IVD (in vitro diagnostics ) products Line, which has been laid out from Tumor early diagnosis , Tumor companion diagnosis field to Oncology dynamic monitoring A series of product development pipelines in the field of , as follows:
-
1) In the field of early diagnosis, based on an independent exosome marker development platform (non-NGS detection method), the company has developed the early stage of ovarian cancer Diagnostic kit. It is worth mentioning that it is China’s the first exosomal diagnostic product to enter a registered clinical trial , And the future price is expected to achieve hundreds of yuan.
Xiong Lei said that for early cancer diagnosis products, performance (sensitivity, specificity, etc.) is a prerequisite, but as a healthy population, users have high price sensitivity, and it is particularly important to achieve universal cost control. Exosomal marker-based detection methods currently have significant cost advantages and can achieve end-of-hundred-dollar prices. At present, the technologies that most companies rely on in the market for research and development are only costing hundreds to thousands of yuan, and it is difficult to reach 90% of the general population to achieve large-scale terminal sales. Didi Didi wants to break this situation.
-
2) In the field of companion diagnostics, the company landed in China’s first fully automated data analysis system in 2018 in 2018; it has a fully automated closed loop developed in 2019 ANDiS400 for gene library preparation has been approved by NMPA, and it is the world ’s first and closed gene library preparation equipment approved in China so far; in addition, there is a series of fully automated platform R & D managementLine and the corresponding companion diagnostic automation product development registration pipeline.
According to Xiong Lei, the successive listing of automation-related pipeline products will solve the dilemma of China’s tumor NGS technology being too large to be implemented in hospitals ; in addition, There is serious qualitative competition, and automation products have significant commercial competitiveness.
He pointed out that China has 4 million new tumors every year, which is calculated based on an average of 3-4 recurrences during the treatment of each patient. This will generate more than 10 million needs for concomitant diagnostic drugs, and only The widespread use of accurate drug diagnosis in thousands of hospitals in China can meet the needs of the tens of millions of companion diagnostics distributed in the above hospitals in the first time, so as not to delay any precise treatment. This requires complicated companions Diagnostic detection and data analysis for automated operation and intelligent analysis .
-
3) In the field of dynamic monitoring, the idea diagnostics is developing thousands of yuan-level products in combination with exosomes platform and molecular diagnostic platform.
The value of dynamic monitoring is that it can track recurrences in time and intervene in a timely manner, and then cooperate with subsequent recurrence detection with diagnostic medications, thereby greatly prolonging the life of advanced patients. In order to truly achieve accurate tracking, the total treatment process of a tumor patient often requires up to 5-10 dynamic monitoring, which also means that the patient needs to bear no small financial burden, but the current market on the market can meet the above needs. Type dynamic monitoring products are almost blank. For this reason, SciDi diagnostics is developing economical and accurate dynamic monitoring products with a cost of 100 yuan, which is expected to be available in 2020 to improve service availability.
To sum up, the idea diagnosis has clear product layout or ideas in three different areas: early diagnosis of tumors, companion diagnosis of tumors, and dynamic monitoring of tumors. Combined with the drug sector, ideas have formed < strong> The overall solution around precision medical treatment of tumors , The company’s initial vision was initially realized < / a>.
On the ground of commercialization, in addition to a number of third-party inspection laboratories that currently provide third-party medical testing services directly to customers, Sidi has established a channel marketing network for IVD companion diagnostic products, covering more than 70% of the core three Level hospital. According to Xiong Lei, as the most mature sector, the companion diagnostics business has reached its growth stage, contributing hundreds of millions of revenues to the company, ranking it in the industryQianmao, as early diagnostic products are approved for market next year, they will also bring in sales.
He also pointed out that, With the explosion of next-generation technologies such as exosomes, protein mass spectrometry, and NGS, as well as the optimization of accurate pathology and imaging artificial intelligence processing technology, the field of accurate diagnosis of tumors will usher in a new situation and opportunity. .
For this reason, as the technology gradually matures and perfects in the next 10 years, the idea of diagnosis will continue to combine with new technology platforms, that is, from the broadening of NGS single technology to mass spectrometry, chemiluminescence and other molecular diagnostic technologies. Combining to develop new products , while improving the performance of accurate tumor diagnosis products, reducing prices-from 10,000 yuan to 100 yuan, to ensure more accessible to patients; on the other hand, also starting Develop precision pathology-related AI technology, and finally cooperate with AI imaging company to achieve the ultimate precision diagnosis solution for tumors .
In this new situation, in recent years, the field of precision tumor medical treatment has also entered the fast track, and the capital enthusiasm of clinical tumor molecular detection and liquid biopsy has not decreased. In the past year, representative companies in the field of precision tumor diagnosis Stone Burning Medicine , Ji Inga , Zhenhe Technology , Universal children , World and genes and so on < span> announced to obtain high financing. In response, Xiong Lei said, The time for large-scale commercialization of the precise tumor diagnosis industry has not yet come. The industry is still in the R & D reserve stage and the initial commercialization period of commercialization, which requires a lot of Funding to support subsequent R & D is inevitable.
However, with the advancement of technology and the gradual clearing of the commercialization route, it is noted that each company has begun to show differences in R & D strategies and R & D focus: For example, Zhenhe Technology continued to expand the introduction of overseas LDT services, and the burning of medical and Pan-born children began to involve early diagnosis based on NGS technology, and Shihe Gene began to expand the field of infection based on NGS. Jiyinga and BGI strategically cooperated to use the latter’s sequencing system to develop products. Continue to be largeFunding for the development of economical early diagnosis and dynamic monitoring products for molecular diagnostic automation and more accessible prices.
Xiong Lei believes that with the large-scale growth of the demand for accurate tumor diagnosis and the requirements for space and quality control, automation will be the trend. Thinking Di Diagnosis also invested a lot of talents for this. It is reported that the company has integrated research and development teams in the field of equipment engineering, electrical, life sciences, materials and data analysis. At present, it has nearly 100 research and development teams, and it is expected that this year will exceed 200.
Investors and FA views:
Tang Yanfa, CEO of China Resources Pharmaceutical Industry Investment Fund:
As the market for targeted drugs and immune drugs continues to expand in the field of tumor therapy, the market for accurate tumor diagnosis will also grow. From 2015 to 2018, the entire NGS-based companion diagnostic industry It has rapidly developed from scratch to a market size of more than 2.5 billion, and early diagnosis and dynamic monitoring are bound to flourish with the application of new technologies in the future. Therefore, the precise tumor diagnosis market has become one of the hot spots for capital investment. SDI has launched an automated closed NGS companion diagnostic platform, which has changed the existing operation model of companion diagnostic NGS business. We are not only optimistic about the development prospects of this automated diagnostic platform, but also optimistic about the multi-technology platform layout of Credith’s three areas of accurate tumor diagnosis.
Eric Capital Founding Partner Irene Hong said:
With the development of modern medicine and diagnostic technology, tumor treatment has gradually entered the era of ‘precision medicine’. In China, as various innovative drugs continue to enter the medical insurance, how will the accompanying diagnosis The landing of ancillary products and services, better guidance to patients on medication, and benefiting more patients are issues of great concern in the medical field. E-Capital is optimistic about the layout of Idea Diagnostics in the NGS automation field and its innovative product pipeline covering three subdivisions of precision diagnosis.
-
-